Impact of PET-FDG in the Diagnosis and Therapeutic Care of Patients Presenting with Metastases of Unknown Primary

REFERENCES

• Abbruzzese J. L., Abbruzzese M. C., Hess K. R., Raber M. N., Lenzi R., Frost P. Unknown primary carcinoma: natural history and pronostic factors in 657 consecutive patients. J. Clin. Oncol. 1994; 12: 1272–1280
   PubMed Web of Science ®Google Scholar
• Abbruzzese J. L., Abbruzzese M. C., Lenzi R., Hess K. R., Raber M. N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J. Clin. Oncol. 1995; 13: 2094–2103
   PubMed Web of Science ®Google Scholar
• Daugaard G. Unknown primary tumors. Cancer Treat. Rev. 1994; 20(2)119–147
   PubMed Web of Science ®Google Scholar
• Nystrom J., Wienner J., Wolph R., Bateman J., Viola M. Identifying the primary site in metastatic cancer of unknown origin: inadequacy of roentgraphyc procedures. JAMA 1979; 241: 381–383
   PubMed Web of Science ®Google Scholar
• Wang R. C., Goepfert H., Barber A. E., Wolf P. Unknown primary squamous cell carcinoma metastatic to the neck. Arch. Otolaryngol. Head Neck Surg. 1990; 116: 1388–1393
   PubMed Web of Science ®Google Scholar
• Hiibner G., Wildfang I., Schmoll H. J. CUP. Kompendium Internistische Onkologie Band 2, H. J. Schmoll. Springer, Berlin-Heidelberg-New York 1999; 2137–2182
   Google Scholar
• Greven K. M., Keyes J. W., William T. J., McGuirt W. F., Joyce W. T. Occult primary tumors of the head and neck. Lack of benefit from positron emission tomography inmaging with 2- (F-18)fluoro-2-deoxy-D-glucose. Cancer 1999; 86: 114–118
   PubMed Web of Science ®Google Scholar
• Gupta N. C., Nicholson P., Bloomfield S. M. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann. Surg. 1999; 230(2)202–206
   PubMed Web of Science ®Google Scholar
• Bohuslavizki K. H., Klutmann S., Kroger S., Sonnemann U., Buchert R., et al. FDG PET detectionof unknown primary tumors. J. Nucl. Med. 2000; 41: 816–822
   PubMed Web of Science ®Google Scholar
• Regelink G., Brouwer J., de Bree R., Pruim J., van der Lan B. F.A.M., et al. Detection of unknown primary tumors and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur. J. Nucl. Med. 2002; 29: 1024–1030
   Google Scholar
• Gutzeit A., Antoch G., Kuhl H., Egelhof T., et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 2005; 234(1)227–34
   PubMed Web of Science ®Google Scholar
• Kole A. C., Nieweg O. E., Pruim J., Hoekstra H. J., Koops H. S., et al. Detection of unknown primary tumors using positron emission tomography. Cancer 1998; 82: 1160–1166
   PubMed Web of Science ®Google Scholar
• Rades D., Kiilnel G., Wildfang I., Borner A. R., Schmoll H. J., Knapp W. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann. Oncol. 2001; 12: 1605–1609
   PubMed Web of Science ®Google Scholar
• Rege S., Maass A., Chaiken L., Hoh C. K., Choi Y., et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancer. Cancer 1994; 73: 3047–3058
   PubMed Web of Science ®Google Scholar
• Mukherji S. K., Drane W. E., Mancuso A. A., Parsons J. T., Mendenhall W. M., Stringer S. Occult primary tumors of the head and neck: detection with 2-(F-18)fluoro-2-deoxy-D-glucose SPECT. Radiology 1996; 199: 761–766
   PubMed Web of Science ®Google Scholar
• Braams J. W., Pruim J., Kole A. C., Nikkels P. G.J., Vaalburg W., et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int. J. Oral. Maxillofac. Surg. 1997; 26: 112–115
   PubMed Web of Science ®Google Scholar
• Hanasono M. M., Kunda L. D., Segall G. M., Ku G. H., Terris D. J. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999; 109: 880–885
   PubMed Web of Science ®Google Scholar
• Aassar O. S., Fischbein N. J., Caputo G. R., Kaplan M. J., Price D. C., et al. Metastatic head and neck cancer : role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210: 177–181
   PubMed Web of Science ®Google Scholar
• Stokkel M. P.M., Terhaard C. H., Hordijk G. J., van Rijk P. P. The detection of unknown primary tumors in patients with cervical metastases by dual-head positron emission tomography. Oral Oncology 1999; 35: 390–394
   PubMed Web of Science ®Google Scholar
• Safa A. A., Tran L. M., Rege S., Brown C. V., Mandelkern M. A., et al. The role of positron emission tomography in occult primary head and neck cancers. Cancer J. Sci. Am. 1999; 5: 214–218
   PubMed Web of Science ®Google Scholar
• Jungehulsing M., Scheidhauer K., Damm M., Pietrzyk U., Ekel H., et al. 2(18F)-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol. Head Neck. Surg. 2000; 123: 294–301
   PubMed Web of Science ®Google Scholar
• Johansen J., Eigtved A., Buchwald C., Theilgaard S. A., Hansen H. S. Implication of 18F- fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 2002; 112: 2009–2014
   PubMed Web of Science ®Google Scholar
• Wong W. L., Saunders M. The impact of FDG PET on the management of primary of occult primary head and neck tumors. Clin. Oncol. (R. Coll. Radiol.) 2003; 15(8)461–466
   PubMed Web of Science ®Google Scholar
• Stoeckli S. J., Mosna-Firlejczk K., Goerres G. W. Lymph node metastasis of squamous cell carcinoma from an unknown pprimary: impact of positron emission tomography. Eur. J. Nucl. Med. 2003; 30: 441–416
   Google Scholar
• Freudenberg L. S., Fischer M., Antoch G., Jentzen W., Gutzeit A., et al. Dual modality of 18F-fluorodeoxyglucose positron emission tomography in patients with cervical carcinoma of unknown primary. Med. Princ. Pract. 2005; 14: 155–160
   PubMed Web of Science ®Google Scholar
• Lassen U., Daugaard G., Eigtved A., Damgaard K., Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumors (UPT). Eur. J. Cancer 1999; 35(7)1076–1082
   PubMed Web of Science ®Google Scholar
• Lonneux M., Reffad A. M. Metastases from unknown primary tumor: PET-FDG as initial staging procedure. Clin. Positron Imaging 2000; 3(4)137–141
   PubMedGoogle Scholar
• Alberini J. L., Belhocine T., Hustinx R., Daenen F., Rigo P. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumors (CUP syndrome). Nucl. Med. Comm. 2003; 24: 1081–1086
   PubMed Web of Science ®Google Scholar
• Mantaka P., Baum R. P., Hertel A., Adams S., Nissen A., et al. PET with 2- (F-18)6fluoro-2-Deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients'diagnostic and therapeutic management. Cancer Biother Radiopharm. 2003; 18: 47–58
   PubMed Web of Science ®Google Scholar
• Nanni C., Rubello D., Castelluci P., Farsad M., Franchi R., Toso S., Barile C., Rampin L., Nibale O., Fanti S. Role of 18 F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results of 21 patients. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 589–592
   PubMed Web of Science ®Google Scholar